Sathy V Balu-Iyer
Overview
Explore the profile of Sathy V Balu-Iyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
958
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies
Jarvi N, Patel M, Shetty K, Nguyen N, Grasperge B, Mager D, et al.
Front Immunol
. 2024 Dec;
15():1496169.
PMID: 39720710
Introduction: Immunogenicity continues to be a challenge for development and clinical utility of monoclonal antibodies, and there are gaps in our current ability to prevent anti-drug antibody development in a...
2.
Jarvi N, Hofman K, Venkatesh A, Gorecki E, Balu-Iyer S
J Pharm Sci
. 2024 Sep;
113(12):3457-3469.
PMID: 39326842
Immunogenicity of gene therapy and the impacts on safety and efficacy are of increasing interest in the pharmaceutical industry. Unique structural aspects of gene therapy delivery vectors, such as adeno-associated...
3.
Jarvi N, Balu-Iyer S
Commun Med (Lond)
. 2023 Dec;
3(1):174.
PMID: 38066254
Background: The efficacy and safety of therapeutic proteins are undermined by immunogenicity driven by anti-drug antibodies. Immunogenicity risk assessment is critically necessary during drug development, but current methods lack predictive...
4.
Nguyen N, Jarvi N, Balu-Iyer S
J Pharm Sci
. 2023 May;
112(9):2347-2370.
PMID: 37220828
The introduction and development of biologics such as therapeutic proteins, gene-, and cell-based therapy have revolutionized the scope of treatment for many diseases. However, a significant portion of the patients...
5.
Nguyen N, Chak V, Keller K, Wu H, Balu-Iyer S
Cell Immunol
. 2022 Dec;
384:104660.
PMID: 36586393
Phosphatidylserine (PS) is an anionic phospholipid exposed on the surface of apoptotic cells. The exposure of PS typically recruits and signals phagocytes to engulf and silently clear these dying cells...
6.
Nguyen N, Chen M, Chak V, Balu-Iyer S
J Pharm Sci
. 2022 Feb;
111(7):2072-2082.
PMID: 35108564
Autoimmune conditions, allergies, and immunogenicity against therapeutic proteins are initiated by the unwanted immune response against self and non-self proteins. The development of tolerance induction approaches can offer an effective...
7.
Bhatta M, Shenoy G, Loyall J, Gray B, Bapardekar M, Conway A, et al.
J Immunother Cancer
. 2021 Oct;
9(10).
PMID: 34599030
Background: The human tumor microenvironment (TME) is a complex and dynamic milieu of diverse acellular and cellular components, creating an immunosuppressive environment, which contributes to tumor progression. We have previously...
8.
Nguyen N, Glassman F, Dingman R, Shenoy G, Wohlfert E, Kay J, et al.
Sci Rep
. 2021 Sep;
11(1):17853.
PMID: 34497305
The safety and efficacy of several life-saving therapeutic proteins are compromised due to their immunogenicity. Once a sustained immune response against a protein-based therapy is established, clinical options that are...
9.
Nguyen N, Dingman R, Balu-Iyer S
J Thromb Haemost
. 2021 Aug;
19(11):2744-2750.
PMID: 34390536
Background: The development of antidrug antibodies, also termed inhibitors, against administered factor VIII (FVIII) is one of the major complications in the clinical management of hemophilia A. Once formed, these...
10.
Hofman K, Shenoy G, Chak V, Balu-Iyer S
Immunol Invest
. 2021 Apr;
50(7):743-779.
PMID: 33929280
COVID-19, the disease caused by the novel severe acute respiratory syndrome-associated coronavirus 2 (SARS-CoV-2), was first detected in December 2019 and has since morphed into a global pandemic claiming over...